Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Krupa Sajan

Physician Assistant Glendale, NY Physician Assistant

NPI 1598401192 CMS profile 11363133

7949 Myrtle Ave, Glendale, NY 11385

Open in the dashboard

General payments

$7,521

357 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krupa Sajan of Glendale, NY is reported in the CMS Open Payments database as having received $7,521 across 357 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,270 113
2024 General $2,050 85
2023 General $2,359 118
2022 General $842 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krupa Sajan
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Krupa Sajan were reported at $2,270. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Krupa Sajan Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $842 $155 $48–$522 $149
2023 $2,359 $167 $52–$557 $160
2024 $2,050 $178 $55–$600 $164
2025 $2,270 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $2,227 121 payments
  2. CSL Behring $869 39 payments
  3. BioCryst US Sales Co., LLC $634 50 payments
  4. AstraZeneca Pharmaceuticals LP $552 24 payments
  5. OptiNose US, Inc. $483 15 payments
  6. Novartis Pharmaceuticals Corporation $440 21 payments
  7. Regeneron Healthcare Solutions, Inc. $374 5 payments
  8. Genzyme Corporation $261 7 payments
  9. Pfizer Inc. $235 11 payments
  10. ARS Pharmaceuticals Operations, Inc. $218 14 payments
  11. Other $1,228 50 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,421 356 payments
  2. Education $100 1 payment
Products named General payments · program years 2022–2025
  1. TRELEGY ELLIPTA $1,330 77 payments
  2. NUCALA $815 39 payments
  3. Haegarda $644 29 payments
  4. Orladeyo $634 50 payments
  5. Xhance $483 15 payments
  6. DUPIXENT Immunology $378 9 payments
  7. XOLAIR $353 14 payments
  8. DUPIXENT Inflammation And Immunology $330 3 payments
  9. TEZSPIRE $280 15 payments
  10. NEFFY $218 14 payments
  11. Other $2,371 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record